<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146116">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01672086</url>
  </required_header>
  <id_info>
    <org_study_id>344-01</org_study_id>
    <nct_id>NCT01672086</nct_id>
  </id_info>
  <brief_title>Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System</brief_title>
  <official_title>Active Surveillance Post-Approval Atudy of the Stelkast Surpass Acetabular System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>StelKast, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>StelKast, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The active surveillance post-approval study of the Stelkast Surpass Acetabular System is a
      retrospective, multi-center, single-arm study intended to collect data on the survivorship
      and long-term safety and effectiveness of the device.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This active surveillance study is intended to evaluate the survivorship and long-term safety
      and effectiveness of the Stelkast Surpass Acetabular System. Neither the patient nor the
      surgeon are blinded to treatment.  The study will compare the Surpass' survivorship to the
      survivorship observed in a historical control group established by a meta-analysis. The
      evaluation will be conducted for a period of ten years. These evaluations will be recorded
      through onsite visits and/or mailings sent to physicians requesting deidentified
      patient-level data for subjects implanted with the Surpass system.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Retrospective</study_design>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">320</enrollment>
  <condition>Survivorship and Long-term Safety and Effectiveness of the Stelkast Surpass Acetabular System</condition>
  <arm_group>
    <arm_group_label>Stelkast Surpass Patients</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Stelkast Surpass Acetabular System implant</intervention_name>
    <arm_group_label>Stelkast Surpass Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients treated with the Stelkast Surpass Acetabular System at the participating
        siteswill be included in the evaluation.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Primary hip arthroplasty

          -  Skeletal maturity

          -  Non-inflammatory degenerative joint disease such as osteoarthritis, avascular
             necrosis, congenital hip dysplasia, and traumatic arthritis

        Exclusion Criteria:

          -  The Stelkast Surpass Acetabular System is contraindicated in patients with the
             following conditions:  Overt or latent infection in or around the hip joint,
             insufficient bone stock to allow appropriate insertion and fixation of the
             prosthesis, insufficient soft tissue integrity to provide adequate stability, muscle
             laxity or inadequate soft tissue for proper function and healing, mental or
             neuromuscular disorders that do not allow control of the affected joint, revision hip
             arthroplasty, inflammatory hip joint disease, and neuropathic hip joint disease.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Abigail Allen</last_name>
    <role>Study Director</role>
    <affiliation>Musculoskeletal Clinical Regulatory Advisers LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gill Orthopedic Clinic</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jennifer Hoffman</last_name>
      <email>jlhoffman@novanthealth.org</email>
    </contact>
    <investigator>
      <last_name>Lowell H Gill, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Orthopedic Specialists</name>
      <address>
        <city>Bryn Mawr</city>
        <state>Pennsylvania</state>
        <zip>19010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy Levenite</last_name>
      <email>clevenite@orthspec.com</email>
    </contact>
    <investigator>
      <last_name>Robert P Good, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mutschler Orthopedic Institute</name>
      <address>
        <city>Canonsburg</city>
        <state>Pennsylvania</state>
        <zip>15317</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Ann Orlando</last_name>
      <email>morlando@wpahs.org</email>
    </contact>
    <investigator>
      <last_name>Thomas A Mutschler, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Premier Orthopedics and SPM Associates</name>
      <address>
        <city>Glen Mills</city>
        <state>Pennsylvania</state>
        <zip>19342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chrissy Bell</last_name>
      <email>cbell@premierortho.com</email>
    </contact>
    <investigator>
      <last_name>Frank P Giammattei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <lastchanged_date>October 31, 2012</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Calcium Carbonate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
